Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787111 · ClinicalTrials.gov registry record · Phase 3
Extended Management and Measurement of Autism
A Phase 3 study, sponsored by Neuropharm.
- Terminated
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT00787111 is a Phase 3 study that was terminated before completion, run by Neuropharm. The registered enrollment target is 128 participants.
The verdict
NCT00787111, a Phase 3 study, was terminated before completion, sponsored by Neuropharm.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month period.
Interventions
- DRUG Fluoxetine (prozac)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787111
The ClinicalTrials.gov registry entry for NCT00787111 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuropharm, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine (prozac) is the first listed.
NCT00787111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787111 about?
NCT00787111 is a clinical study titled "Extended Management and Measurement of Autism". This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month perio...
What is the current status of trial NCT00787111?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2008-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00787111?
The interventions under investigation include: Fluoxetine (prozac) (DRUG).
Who is sponsoring clinical trial NCT00787111?
This trial is sponsored by Neuropharm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.